Insider Selling: BiomX (NYSEAMERICAN:PHGE) Director Sells 450,000 Shares of Stock

BiomX Inc. (NYSEAMERICAN:PHGE) Director Reuven Yeganeh sold 450,000 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $5.00, for a total value of $2,250,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Reuven Yeganeh also recently made the following trade(s):

• On Tuesday, March 17th, Reuven Yeganeh sold 530,000 shares of BiomX stock. The stock was sold at an average price of $5.00, for a total value of $2,650,000.00.

BiomX Trading Down 3.6%

PHGE stock traded down $0.19 during trading on Wednesday, hitting $5.04. 52,934 shares of the company’s stock were exchanged, compared to its average volume of 1,183,020. The business has a 50-day moving average price of $4.86 and a two-hundred day moving average price of $6.36. The stock has a market capitalization of $8.01 million, a price-to-earnings ratio of -0.20 and a beta of 1.68. BiomX Inc. has a 52-week low of $1.50 and a 52-week high of $14.71.

BiomX (NYSEAMERICAN:PHGE) last announced its quarterly earnings results on Thursday, February 19th. The company reported $6.99 EPS for the quarter. On average, equities research analysts anticipate that BiomX Inc. will post -2.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright downgraded shares of BiomX from a “buy” rating to a “hold” rating in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $26.00.

Institutional Trading of BiomX

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC purchased a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned about 0.61% of BiomX as of its most recent SEC filing. 40.57% of the stock is currently owned by hedge funds and other institutional investors.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.